Revance Therapeutics, Inc. clinical trials

Acquired by Revance, Feb 6, 2025 · source ↗

The registry lists 29 studies whose lead sponsor is Revance Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 4, 2025.

Studies

Recruiting first, then most recently updated. Showing 29 of 29. All Revance studies →

• Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar LinesCompletedNCT06411002Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• DaxibotulinumtoxinA for Injection for the Management of Plantar FasciitisTerminatedNCT02973269Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb SpasticityCompletedNCT03821402Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• DaxibotulinumtoxinA for Injection for the Treatment of Plantar FasciitisCompletedNCT03825315Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar FasciitisCompletedNCT03137407Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial LinesCompletedNCT04259086Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal LinesCompletedNCT03911102Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)CompletedNCT03786770Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)CompletedNCT03608397Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar LinesCompletedNCT03014635Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar LinesCompletedNCT03014622Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar LinesCompletedNCT03004248Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)CompletedNCT03617367Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Teosyal RHA® Histology and Intradermal Implantation Evaluation StudyStatus unknownNCT04846530

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00884234Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsCompletedNCT01064518Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical DystoniaCompletedNCT02706795Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal LinesCompletedNCT02580370Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary HyperhidrosisCompletedNCT02565732Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar LinesCompletedNCT02303002Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet LinesTerminatedNCT01818076Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet LinesCompletedNCT01776606Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet LinesCompletedNCT01940991Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsCompletedNCT01124552Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsCompletedNCT01124565Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00907387Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00968825Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00888914Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00968942Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance